Oncology
3 drugs are in development for Metastatic Colorectal Cancer.
- Companies
- 2
- Clinical trials
- 43
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Metastatic Colorectal Cancer pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| CTX-009 | Compass Therapeutics, Inc. (CMPX) |
Phase 1/Phase 2(1)
| Drug | Company |
|---|---|
| ERAS-007 | Erasca, Inc. (ERAS) |
Phase 2/Phase 3(1)
About this indication
Metastatic Colorectal Cancer context
Oncology·MeSH: Colorectal Neoplasms (D015179)
Narrower concept of MeSH descriptor Colorectal Neoplasms
Prevalence
135.0 / 100K
Incidence
36.0 / 100K/yr
Frequently asked questions
How many drugs are in development for Metastatic Colorectal Cancer?
BioSniper tracks 3 drugs in development for Metastatic Colorectal Cancer across 2 companies.
How many clinical trials target Metastatic Colorectal Cancer?
There are 43 clinical trials targeting Metastatic Colorectal Cancer tracked by BioSniper.
What is the prevalence of Metastatic Colorectal Cancer?
The estimated prevalence of Metastatic Colorectal Cancer is approximately 135.0 per 100,000 population.